LifeMD, Inc. (LFMDP)
USD 22.12
(1.28%)
USD 22.12
(1.28%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 52.91 Million USD | 60.49% |
| 2022 | 32.97 Million USD | 36.79% |
| 2021 | 24.1 Million USD | 73.72% |
| 2020 | 13.87 Million USD | 203.26% |
| 2019 | 4.57 Million USD | 154.7% |
| 2018 | 1.79 Million USD | 180.26% |
| 2017 | 640.97 Thousand USD | -44.34% |
| 2016 | 1.15 Million USD | 330.52% |
| 2015 | 267.48 Thousand USD | -15.01% |
| 2014 | 314.71 Thousand USD | -11.59% |
| 2013 | 355.96 Thousand USD | 51.67% |
| 2012 | 234.69 Thousand USD | -62.53% |
| 2011 | 626.31 Thousand USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 65.87 Million USD | 9.51% |
| 2024 Q1 | 60.15 Million USD | 13.69% |
| 2023 Q1 | 41.23 Million USD | 25.05% |
| 2023 Q4 | 52.91 Million USD | 2.2% |
| 2023 Q2 | 45.65 Million USD | 10.72% |
| 2023 Q3 | 51.77 Million USD | 13.41% |
| 2023 FY | 52.91 Million USD | 60.49% |
| 2022 Q3 | 30.27 Million USD | -2.81% |
| 2022 Q2 | 31.15 Million USD | -8.19% |
| 2022 Q1 | 33.93 Million USD | 40.79% |
| 2022 FY | 32.97 Million USD | 36.79% |
| 2022 Q4 | 32.97 Million USD | 8.89% |
| 2021 FY | 24.1 Million USD | 73.72% |
| 2021 Q3 | 31.01 Million USD | 10.22% |
| 2021 Q4 | 24.1 Million USD | -22.28% |
| 2021 Q2 | 28.13 Million USD | 78.02% |
| 2021 Q1 | 15.8 Million USD | 13.92% |
| 2020 Q3 | 13.39 Million USD | 69.46% |
| 2020 FY | 13.87 Million USD | 203.26% |
| 2020 Q1 | 6 Million USD | 31.15% |
| 2020 Q2 | 7.9 Million USD | 31.72% |
| 2020 Q4 | 13.87 Million USD | 3.59% |
| 2019 Q2 | 3.62 Million USD | 50.89% |
| 2019 Q1 | 2.4 Million USD | 33.85% |
| 2019 Q4 | 4.57 Million USD | 46.92% |
| 2019 FY | 4.57 Million USD | 154.7% |
| 2019 Q3 | 3.11 Million USD | -14.16% |
| 2018 Q3 | 699.88 Thousand USD | 36.84% |
| 2018 FY | 1.79 Million USD | 180.26% |
| 2018 Q4 | 1.79 Million USD | 156.67% |
| 2018 Q2 | 511.46 Thousand USD | 60.64% |
| 2018 Q1 | 318.4 Thousand USD | -50.33% |
| 2017 Q1 | 2.39 Million USD | 108.16% |
| 2017 Q2 | 1.59 Million USD | -33.63% |
| 2017 Q3 | 776.98 Thousand USD | -51.16% |
| 2017 Q4 | 640.97 Thousand USD | -17.51% |
| 2017 FY | 640.97 Thousand USD | -44.34% |
| 2016 Q3 | 622.3 Thousand USD | 19.3% |
| 2016 FY | 1.15 Million USD | 330.52% |
| 2016 Q1 | 436.96 Thousand USD | 63.36% |
| 2016 Q2 | 521.64 Thousand USD | 19.38% |
| 2016 Q4 | 1.15 Million USD | 85.04% |
| 2015 Q2 | 417.27 Thousand USD | 18.44% |
| 2015 Q4 | 267.48 Thousand USD | -29.95% |
| 2015 Q3 | 381.85 Thousand USD | -8.49% |
| 2015 Q1 | 352.29 Thousand USD | 11.94% |
| 2015 FY | 267.48 Thousand USD | -15.01% |
| 2014 Q2 | 287.62 Thousand USD | 17.4% |
| 2014 Q1 | 244.98 Thousand USD | -31.18% |
| 2014 Q4 | 314.71 Thousand USD | -8.47% |
| 2014 Q3 | 343.84 Thousand USD | 19.55% |
| 2014 FY | 314.71 Thousand USD | -11.59% |
| 2013 Q2 | 281.66 Thousand USD | 15.21% |
| 2013 Q1 | 244.47 Thousand USD | 4.17% |
| 2013 FY | 355.96 Thousand USD | 51.67% |
| 2013 Q4 | 355.96 Thousand USD | 41.15% |
| 2013 Q3 | 252.18 Thousand USD | -10.47% |
| 2012 Q3 | 209.39 Thousand USD | 0.0% |
| 2012 FY | 234.69 Thousand USD | -62.53% |
| 2012 Q4 | 234.69 Thousand USD | 12.08% |
| 2011 FY | 626.31 Thousand USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| CannBioRx Life Sciences Corp. | 5.38 Million USD | -882.226% |
| BIMI International Medical Inc. | 30.49 Million USD | -73.506% |
| China Jo-Jo Drugstores, Inc. | 80.76 Million USD | 34.482% |
| Harrow Health, Inc. 8.625% Senior Notes due 2026 | 241.75 Million USD | 78.112% |
| Harrow Health, Inc. 11.875% Senior Notes due 2027 | 241.75 Million USD | 78.112% |
| Leafly Holdings, Inc. | 34.29 Million USD | -54.301% |
| Leafly Holdings, Inc. | 34.29 Million USD | -54.301% |
| LifeMD, Inc. | 52.91 Million USD | 0.0% |
| TRxADE HEALTH, Inc. | 11.99 Million USD | -341.302% |
| PetMed Express, Inc. | 78.36 Million USD | 32.474% |
| Walgreens Boots Alliance, Inc. | 68.85 Billion USD | 99.923% |